mRNA |
Gefitinib |
CTRPv2 |
pan-cancer |
AAC |
0.007 |
0.8 |
mRNA |
IU1 |
CTRPv2 |
pan-cancer |
AAC |
-0.0074 |
0.8 |
mRNA |
MK 1775 |
CTRPv2 |
pan-cancer |
AAC |
-0.0064 |
0.8 |
mRNA |
BCL-LZH-4 |
CTRPv2 |
pan-cancer |
AAC |
0.01 |
0.8 |
mRNA |
tanespimycin:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.007 |
0.9 |
mRNA |
WAY-362450 |
CTRPv2 |
pan-cancer |
AAC |
-0.0068 |
0.9 |
mRNA |
CIL70 |
CTRPv2 |
pan-cancer |
AAC |
0.0087 |
0.9 |
mRNA |
CD-1530 |
CTRPv2 |
pan-cancer |
AAC |
0.0067 |
0.9 |
mRNA |
decitabine:carboplatin (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.0049 |
0.9 |
mRNA |
Doxorubicin |
CTRPv2 |
pan-cancer |
AAC |
0.0052 |
0.9 |